Matti A. Rookus

12.6k citations

65 papers · 2.7k indexed · h-index 30

Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment 14
Genetics top 1%
- BRCA gene mutations in cancer 35
- Genomic variations and chromosomal abnormalities 10
- Nutrition, Genetics, and Disease 6
Cancer Research top 2%
- Cancer Genomics and Diagnostics 12
Oncology top 2%
- Cancer Risks and Factors 18
- Global Cancer Incidence and Screening 6
Pathology and Forensic Medicine top 2%
Endocrinology, Diabetes and Metabolism
- Growth Hormone and Insulin-like Growth Factors 6

Co-authors: Flora E. van Leeuwen Laura J. van’t Veer Richard M. Brohet Janneke Verloop Christi J. van Asperen K van der Kooy Hans F. A. Vasen Dorien W. Voskuil
Cited by: Reproductive Medicine Genetics Cancer Research
Journals: JAMA (1 paper)Journal of Clinical Oncology (3 papers)Gastroenterology (1 paper)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Matti A. Rookus

60 papers receiving 2.7k citations

Peers

Countries citing papers authored by Matti A. Rookus

Since Specialization

Citations

This map shows the geographic impact of Matti A. Rookus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matti A. Rookus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matti A. Rookus more than expected).

Fields of papers citing papers by Matti A. Rookus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matti A. Rookus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matti A. Rookus. The network helps show where Matti A. Rookus may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matti A. Rookus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matti A. Rookus Line = papers co-authored together Matti A. Rookus links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cancer risk after in utero exposure to diethylstilbestrol European Journal of Epidemiology ·Naomi B. Boekel,Janneke Verloop,Hester H. van Boven,E.J.M. van Erp,Lieske H. Schrijver,Matti A. Rookus,Flora E. van Leeuwen	2025	0
2	Tumour-educated platelets for breast cancer detection: biological and technical insights British Journal of Cancer ·Marte C. Liefaard,Kat Moore,Lennart Mulder,Daan van den Broek,Jelle Wesseling,Gabe S. Sonke,Lodewyk F.A. Wessels,Matti A. Rookus,Esther H. Lips	2023	14
3	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits JNCI Journal of the National Cancer Institute ·Lieske H. Schrijver,Thea M. Mooij,Anouk Pijpe,Gabe S. Sonke,Marian J.E. Mourits,Nadine Andrieu,Antonis C. Antoniou,Douglas F. Easton,Christoph Engel,David E. Goldgar,Esther M. John,Karin Kast,Roger L. Milne,Håkan Olsson,Kelly‐Anne Phillips,Mary Beth Terry,John L. Hopper,Flora E. van Leeuwen,Matti A. Rookus	2022	7
4	Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study Breast Cancer Research and Treatment ·Mark van Barele,Amy Rieborn,B.A.M. Heemskerk-Gerritsen,Inge-Marie Obdeijn,Linetta B. Koppert,Claudette E. Loo,Rob A.�E.�M. Tollenaar,Margreet G.E.M. Ausems,Irma van de Beek,Lieke P. V. Berger,Maaike de Boer,Liselot P. van Hest,C. Marleen Kets,Matti A. Rookus,(unknown),Marjanka K. Schmidt,Agnes Jager,Maartje J. Hooning	2022	0
5	Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study JNCI Journal of the National Cancer Institute ·Marthe M. de Jonge,Cor D. de Kroon,Denise J. Jenner,Jan Oosting,Joanne A. de Hullu,Marian J.E. Mourits,E. Gómez,Margreet G.E.M. Ausems,J. Margriet Collée,Klaartje van Engelen,Irma van de Beek,(unknown),Vincent T.H.B.M. Smit,Matti A. Rookus,Geertruida H. de Bock,Flora E. van Leeuwen,Tjalling Bosse,Olaf M. Dekkers,Christi J. van Asperen	2021	42
6	Germline BRCA -Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity Clinical Cancer Research ·Marthe M. de Jonge,Lauren L. Ritterhouse,Cor D. de Kroon,Maaike P.G. Vreeswijk,Jeremy P. Segal,Rutika Puranik,Harry Hollema,Matti A. Rookus,Christi J. van Asperen,Flora E. van Leeuwen,Vincent T.H.B.M. Smit,Brooke E. Howitt,Tjalling Bosse	2019	34
7	RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer Annals of Oncology ·Marte C. Liefaard,Esther H. Lips,Myron G. Best,Nik Sol,Sjors G. J. G. In ‘t Veld,Matti A. Rookus,Gabe S. Sonke,B.A. Tannous,Jelle Wesseling,Thomas Würdinger	2019	7
8	The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position? European Journal of Human Genetics ·(unknown),Natália Teixeira,Annemieke van der Hout,Jan C. Oosterwijk,Janet R. Vos,Peter Devilee,Klaartje van Engelen,Hanne Meijers‐Heijboer,Rob B. van der Luijt,Mieke Kriege,Arjen R. Mensenkamp,Matti A. Rookus,Kees E. van Roozendaal,Marian J.E. Mourits,Geertruida H. de Bock	2018	6
9	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers Cancer Epidemiology Biomarkers & Prevention ·Janet R. Vos,Jan C. Oosterwijk,Cora M. Aalfs,Matti A. Rookus,Muriel A. Adank,Annemarie H. van der Hout,Christi J. van Asperen,E. Gómez,Arjen R. Mensenkamp,Agnes Jager,Margreet G.E.M. Ausems,Marian J.E. Mourits,Geertruida H. de Bock	2016	5
10	Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughters Gynecologic Oncology ·Janneke Verloop,Flora E. van Leeuwen,Th.J.M. Helmerhorst,Inge M.C.M. de Kok,E.J.M. van Erp,Hester H. van Boven,Matti A. Rookus	2016	5
11	Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction JNCI Journal of the National Cancer Institute ·B.A.M. Heemskerk-Gerritsen,Caroline Seynaeve,C. J. van Asperen,Margreet G.E.M. Ausems,J.M. Collée,Helena C. van Doorn,E. Gómez,C. Marleen Kets,Flora E. van Leeuwen,Hanne Meijers‐Heijboer,Marian J.E. Mourits,Theo A.M. van Os,Hans F. A. Vasen,Senno Verhoef,Matti A. Rookus,Maartje J. Hooning	2015	133
12	BRCA1/2 mutation carriers do not have earlier natural menopause compared to proven non-carriers: report from the Dutch hereditary breast and ovarian cancer study group (HEBON) University of Groningen research database (University of Groningen / Centre for Information Technology) ·Madelon van Wely,Frank J. Broekmans,Lieske H. Schrijver,Thea M. Mooij,Anouk Pijpe,JC Oosterwijk,(unknown),(unknown),Wendy A.G. van Zelst–Stams,Muriel A. Adank,C. J. van Asperen,Helena C. van Doorn,(unknown),Matti A. Rookus,Margreet G.E.M. Ausems	2014	1
13	Improved overall survival after contralateral risk‐reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis International Journal of Cancer ·B.A.M. Heemskerk-Gerritsen,Matti A. Rookus,Cora M. Aalfs,Margreet G.E.M. Ausems,J.M. Collée,Liesbeth Jansen,C. Marleen Kets,Kristien Keymeulen,Linetta B. Koppert,Hanne Meijers-Heijboer,Thea M. Mooij,Rob A.�E.�M. Tollenaar,Hans F. A. Vasen,HEBON,Maartje J. Hooning,Caroline Seynaeve	2014	130
14	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations Journal of Medical Genetics ·Richard M. Brohet,Maria E. Velthuizen,Frans B.L. Hogervorst,Hanne Meijers‐Heijboer,Caroline Seynaeve,Margriet J Collée,Senno Verhoef,Margreet G.E.M. Ausems,Nicoline Hoogerbrugge,Christi J. van Asperen,E. Gómez,Fred H. Menko,Jan C. Oosterwijk,Peter Devilee,Laura J. van’t Veer,Flora E. van Leeuwen,Douglas F. Easton,Matti A. Rookus,Antonis C. Antoniou,(unknown)	2013	62
15	Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers Journal of Clinical Epidemiology ·Anouk Pijpe,Renée L. Mulder,Peggy Manders,Flora E. van Leeuwen,Matti A. Rookus	2011	6
16	Body weight and risk of breast cancer in BRCA1/2 mutation carriers Breast Cancer Research and Treatment ·(unknown),Peggy Manders,Anouk Pijpe,Maartje J. Hooning,Irma Kluijt,Hans F. A. Vasen,Nicoline Hoogerbrugge,Christi J. van Asperen,Hanne Meijers‐Heijboer,Margreet G.E.M. Ausems,Theo A. van Os,E. Gómez,Richard M. Brohet,Flora E. van Leeuwen,Matti A. Rookus	2010	43
17	No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study British Journal of Cancer ·Brenda Hermsen,R.I. Olivier,René H.M. Verheijen,Marc van Beurden,Joanne A. de Hullu,Leon F.A.G. Massuger,Curt W. Burger,Cecile T.M. Brekelmans,M J E Mourits,Geertruida H. de Bock,Katja N. Gaarenstroom,Hester H. van Boven,Thea M. Mooij,Matti A. Rookus	2007	104
18	Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up British Journal of Cancer ·R.I. Olivier,Marc van Beurden,M.A.C. Lubsen,Matti A. Rookus,Thea M. Mooij,Marc J. van de Vijver,Laura J. van’t Veer	2004	92
19	Physical Activity and Breast Cancer Risk in Women Aged 20-54 Years JNCI Journal of the National Cancer Institute ·Janneke Verloop,Matti A. Rookus,K van der Kooy,Flora E. van Leeuwen	2000	165
20	Induced Abortion and Risk for Breast Cancer: Reporting (Recall) Bias in a Dutch Case-Control Study JNCI Journal of the National Cancer Institute ·Matti A. Rookus,Flora E. van Leeuwen	1996	45

About Matti A. Rookus

Matti A. Rookus is a scholar working on Reproductive Medicine, Genetics and Oncology, having authored 65 papers that have together received 2.7k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (35 papers), Cancer Risks and Factors (18 papers), Ovarian cancer diagnosis and treatment (14 papers), Cancer Genomics and Diagnostics (12 papers), Genomic variations and chromosomal abnormalities (10 papers), Nutrition, Genetics, and Disease (6 papers), Growth Hormone and Insulin-like Growth Factors (6 papers) and Global Cancer Incidence and Screening (6 papers). The work is most often cited by research in Reproductive Medicine (550 citations), Genetics (1.5k citations) and Cancer Research (729 citations). Matti A. Rookus has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Flora E. van Leeuwen, Laura J. van’t Veer, Richard M. Brohet, Janneke Verloop, Christi J. van Asperen, K van der Kooy, Hans F. A. Vasen, Dorien W. Voskuil, Margreet G.E.M. Ausems and Emiel J. Rutgers. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact